Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    82.55
    -0.26 (-0.31%)
     
  • GOLD FUTURES

    2,339.30
    +0.90 (+0.04%)
     
  • DOW

    37,993.82
    -467.10 (-1.21%)
     
  • Bitcoin GBP

    51,526.83
    -308.91 (-0.60%)
     
  • CMC Crypto 200

    1,394.50
    +11.93 (+0.86%)
     
  • NASDAQ Composite

    15,528.20
    -184.55 (-1.17%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Why Esperion Therapeutics Plummeted Nearly 22% Today

Why Esperion Therapeutics Plummeted Nearly 22% Today

Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).